Status: Recruiting
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 2-18Biological sex: AllType: InterventionalSponsor: Praxis Precision MedicinesUpdated: Aug 21, 2025Locations: 3
Eligibility criteria
Has onset of seizures prior to 3 months of age. [+3]
Has any clinically significant or known pathogenic genetic variant other than in... [+2]